Publication | Closed Access
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
99
Citations
15
References
2012
Year
nab-Paclitaxel was well tolerated, and it demonstrated preliminary evidence of activity in a subset of patients who progressed on gemcitabine-based therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1